Corbus Pharmaceuticals (CRBP) News Today $7.23 -0.13 (-1.77%) Closing price 04:00 PM EasternExtended Trading$7.30 +0.07 (+0.97%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Recommendation of "Buy" from BrokeragesMay 23, 2025 | americanbankingnews.comMizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)May 22, 2025 | theglobeandmail.comCorbus Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $2.86 Million Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Tang Capital Management LLC trimmed its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 59.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 242,653 shares of the biopharmaceutical compaMay 20, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by AnalystsShares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received an average rating of "Buy" from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has given a strMay 20, 2025 | marketbeat.comCorbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board ChairMay 19, 2025 | finance.yahoo.comProsight Management LP Purchases 140,000 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Prosight Management LP increased its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 107.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 270,000 shares of the biopharmaceMay 17, 2025 | marketbeat.comOrbimed Advisors LLC Raises Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Orbimed Advisors LLC grew its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 28.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,172,287 shares of the biopharmaceutical company's stock after buying an additional 259,735 sharesMay 15, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLCBarclays PLC lessened its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 85.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,156 shares of the biopharmaceutical company's stock after sellingMay 15, 2025 | marketbeat.comQ2 EPS Forecast for Corbus Pharmaceuticals Cut by AnalystCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at B. Riley decreased their Q2 2025 earnings estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the biopharmaMay 11, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of CRBP Q2 EarningsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now anticipMay 11, 2025 | marketbeat.comQ2 EPS Estimates for Corbus Pharmaceuticals Cut by WedbushCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at Wedbush decreased their Q2 2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst R. Driscoll now anticipatesMay 11, 2025 | marketbeat.comQ2 Earnings Estimate for CRBP Issued By William BlairCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at William Blair issued their Q2 2025 earnings estimates for Corbus Pharmaceuticals in a report issued on Tuesday, May 6th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical companyMay 11, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 160,933 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Price T Rowe Associates Inc. MD cut its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 49.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,735 shares of the biopharMay 10, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Given New $56.00 Price Target at OppenheimerOppenheimer cut their target price on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday.May 9, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $40.00 by Analysts at HC WainwrightHC Wainwright dropped their price target on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Posts Earnings Results, Misses Expectations By $0.13 EPSCorbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13).May 8, 2025 | marketbeat.comCorbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 8, 2025 | finance.yahoo.comCorbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 7, 2025 | finance.yahoo.comBoothbay Fund Management LLC Decreases Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Boothbay Fund Management LLC reduced its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 75.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,534 shares of the biopharmaceutical compMay 6, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on TuesdayCorbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-corbus-pharmaceuticals-holdings-inc-stock/)May 1, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC grew its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 769.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,10April 29, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Buy" by BrokeragesShares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has given a stronApril 25, 2025 | marketbeat.comAltium Capital Management LLC Raises Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Altium Capital Management LLC boosted its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 97.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 385,000 shares of the biopharmaceutical compApril 20, 2025 | marketbeat.comWe Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business GrowthApril 18, 2025 | finance.yahoo.comCorbus Pharmaceuticals management to meet with Piper SandlerApril 17, 2025 | markets.businessinsider.comCorbus announces first patient dosed in Phase 1 CRB-913 studyMarch 28, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of ObesityMarch 28, 2025 | globenewswire.comB. Riley Lifts Earnings Estimates for Corbus PharmaceuticalsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley raised their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel now anticipatesMarch 17, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for CRBP EarningsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that theMarch 17, 2025 | marketbeat.comWhat is B. Riley's Forecast for CRBP Q1 Earnings?Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at B. Riley issued their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical comMarch 15, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for CRBP Q1 Earnings?Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at Lifesci Capital boosted their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now forecasts that the biopharmaceutical comMarch 15, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)Wedbush reissued an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday.March 13, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday.March 13, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Gets a Buy from RBC CapitalMarch 12, 2025 | markets.businessinsider.comJefferies Financial Group Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00Jefferies Financial Group dropped their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research report on Tuesday.March 12, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPSCorbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24.March 12, 2025 | marketbeat.comCorbus Pharmaceuticals price target lowered to $53 from $70 at JefferiesMarch 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals (CRBP) Gets a Buy from William BlairMarch 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.comStockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday.March 7, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms marketMarch 5, 2025 | marketwatch.comCorbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William BlairWilliam Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday. They set an "outperform" rating for the company.March 1, 2025 | marketbeat.comCorbus Pharmaceuticals initiated with an Outperform at William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform RecommendationFebruary 28, 2025 | msn.comCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | finance.yahoo.comCorbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday.February 19, 2025 | marketbeat.comMizuho Securities Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)February 16, 2025 | markets.businessinsider.comCorbus Pharmaceuticals announces data from its US, UK study of CRB-701February 14, 2025 | markets.businessinsider.comCorbus Pharmaceuticals falls after trial data for lead assetFebruary 14, 2025 | msn.comRBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)February 14, 2025 | markets.businessinsider.com Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Media Mentions By Week CRBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBP News Sentiment▼0.931.03▲Average Medical News Sentiment CRBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBP Articles This Week▼43▲CRBP Articles Average Week Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ABVX News MREO News PRTA News CKPT News FULC News ERAS News OLMA News SNDL News BNTC News CGC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBP) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Makes Major Crypto AnnouncementYou Won’t Get a Second Chance at This Entry The crypto comeback isn't coming—it's already here. And one ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRBP Stock Free CRBP Stock Alerts